



Stelara in India

The CDSCO named-patient coordination pathway — indicative 2026

IMMUNOLOGY · IL-12 / IL-23

The clinical situation

Stelara (ustekinumab) is an FDA-approved fully human monoclonal antibody to the p40 subunit shared by IL-12 and IL-23 indicated for plaque psoriasis, psoriatic arthritis, Crohn disease, and ulcerative colitis. Manufactured by Janssen. Standard dosing is weight-based SC induction then 45 or 90 mg every 8-12 weeks (psoriasis), with indication-specific IV induction for IBD; refrigerated storage 2-8°C, provider-administered or patient pre-filled syringe.

The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your treating dermatologist, rheumatologist, or gastroenterologist documents diagnosis severity, TB/HBV/HCV screening, and prior biologic history.
- 2 Treating centre confirmed.** An Indian tertiary centre in Mumbai, Delhi, Bengaluru, or Chennai accepts the case.
- 3 CDSCO named-patient application.** Clinical rationale, patient reference, product details, and cold-chain plan are filed under CDSCO's personal-import pathway.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner; temperature-monitored 2-8°C shipment.
- 5 Arrival & administration.** SC maintenance dosing self-administered or at the centre; IV induction centre-based; response reassessed at 12-16 weeks.

Indicative economics

Reference US cash-pay range: USD 25,000–30,000 per quarterly dose. CDSCO documentation, cold-chain logistics, and concierge coordination are incremental. Full transparent quote at intake.

Indicative first-dose timing

7–14 days from a complete CDSCO application to first-dose delivery, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your physician and CDSCO review. **Logistics.** Temperature-monitored cold-chain shipment coordination. **Concierge case lead.** Named point of contact for family and physician through the full process. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating specialist.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Stelara × India first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/stelara-india.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team